How many manufacturers are there for Nintedanib? Is the market competition fierce?

Nintedanib (Nintedanib) is an anti-fibrotic drug developed by Bayer and is widely used to treat idiopathicpulmonary fibrosis and other diseases related to lung fibrosis. As the original manufacturer of the drug, Bayer is responsible for the global promotion and sales of nintedanib.

1. Domestic market:The original drug of nintedanib has been launched. The common packaging specifications are100mg30 capsules/box and 150mg30 capsules/box. The prices of these original drugs are relatively high, usually around several thousand yuan. The quality and efficacy of the original nintedanib drug have been rigorously verified, and it has strong market recognition. Especially in the treatment of diseases such as idiopathic pulmonary fibrosis, it has attracted widespread attention from clinicians and patients.

2. Overseas markets

1) Original drug: There are also nintedanib drugs produced by other companies on the international market, mainly from countries such as Türkiye and India. The manufacturers of nintedanib in these areas are mainly Bayer's authorized production partners. The production specifications are 100mg 60 tablets or 150mg 60 tablets, and the price is usually between 4,000 and 5,000 yuan.

2) Generic drugs: There are many generic drug manufacturers on the market producing generic ninidab drugs. The most common generic drug manufacturers include India's BDR Company, Grammark Pharmaceuticals and Laos' ASEAN Pharmaceuticals. The ingredients and efficacy of generic nintedanib drugs are similar to those of the original drug, so the price is relatively cheap, usually around RMB 600 (subject to adjustment based on exchange rate fluctuations).

Although there are multiple manufacturers producing nintedanib on the market, including original drugs and generic drugs, the original drugs still dominate the market due to their advantages in efficacy and quality. However, as the prices of generic drugs gradually decrease, market competition gradually intensifies. Especially in developing countries, the price advantage of generic drugs has attracted more patients to choose generic drugs.

Keyword tags: nintedanib,Nintedanib, manufacturer, market competition, original drug, generic drug, price, quality of generic drug

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/ofev